Avastin / Altuzan (bevacizumab) 400 mg, Roche, Germany Avastin (bevacizumab) is used for approved indications including metastatic colorectal cancer. International medicine delivery within 4-5 days. Order at +380996042415 via Viber or WhatsApp.

indications

treatment of metastatic colorectal cancer in adult patients in combination with chemotherapy based on fluoropyrimidine derivatives.

treatment of metastatic breast cancer in adult patients:

first line of treatment in combination with paclitaxel;

first line of treatment in combination with capecitabine (when treatment with other chemotherapy regimens, including taxanes or anthracyclines, is considered inappropriate). Patients who have received taxane- and anthracycline-based regimens in the adjuvant setting within the past 12 months should not receive Zirabev in combination with capecitabine.

Treatment in adult patients of unresectable advanced, metastatic or recurrent non-small cell lung cancer, except for predominantly squamous cell histology:

first line of treatment in combination with chemotherapy based on platinum derivatives.

Treatment of advanced and/or metastatic renal cell cancer in adult patients:

first line of treatment in combination with interferon alpha-2a.

Treatment of advanced (stages III B III C and IV according to the International Federation of Obstetrics and Gynecology (FIGO) classification of epithelial cancer ovarian, fallopian tube and primary peritoneal cancer in adult patients:

first line of treatment in combination with carboplatin and paclitaxel

Treatment of the first relapse of epithelial ovarian, fallopian tube and primary peritoneal cancer sensitive to treatment with platinum drugs in combination with carboplatin and paclitaxel in adult patients, not previously treated with bevacizumab or other VEGF inhibitors. Treatment of recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer, resistant to treatment with platinum drugs in combination with topotecan or pegylated liposomal doxorubicin in adult patients who have received no more than two previous chemotherapy regimens or drugs whose action is directed to the VEGF receptor. recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or alternatively paclitaxel and topotecan in adult patients who cannot receive platinum therapy.